Hefiya (Adalimumab)

Hefiya is approved for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, inflammatory bowel disease (Crohn’s disease and ulcerative colitis), plaque psoriasis, and hidradenitis suppurativa.

Adalimumab binds to tumor necrosis factor‑alpha (TNF‑α) and neutralizes its activity, thereby interrupting the inflammatory cascade that drives symptoms in autoimmune conditions.

Common adverse events include injection‑site reactions, mild upper‑respiratory infections, headache, and occasional skin rash or itching.

Serious risks include severe infections (such as tuberculosis), certain cancers, demyelinating neurologic disorders, and worsening heart failure. Patients should be monitored regularly.

Yes. Patients should be screened for latent tuberculosis, hepatitis B infection, and evaluated for any active infections or malignancies before initiating therapy.

Live vaccines should be avoided during treatment. Inactivated vaccines can be administered, but timing should be coordinated with the prescribing clinician.

The safety of adalimumab in pregnancy and lactation has not been fully established. Decisions should be made jointly with a healthcare provider, weighing potential benefits and risks.

Report any signs of infection promptly. The prescribing physician may temporarily discontinue Hefiya and initiate appropriate antimicrobial therapy.

Yes. Inform your doctor about all concomitant medications, especially other biologics, immunosuppressants, systemic steroids, and antiviral agents for hepatitis B, as they may require dose adjustments or monitoring.

Dosage is individualized based on the specific indication, patient weight, and clinical response, and is prescribed by a qualified healthcare professional.

Regular clinical assessments, laboratory tests for liver function, complete blood count, and screening for infections are recommended throughout treatment.